Following the UK’s triggering of Article 50 to leave the European Union, the HPRA, together with medicines agencies in Europe, is making preparations to ensure that we continue to deliver on our patient and animal health remit even if the UK fully exits the current systems on 29 March 2019.

The aim of the meeting was to engage with stakeholders on approach to potential Brexit scenarios, to outline plans to increase contribution to EU regulatory procedures as may be required, and to understand the concerns and requirements of different stakeholder groups. The meeting was focus on medicines for human and veterinary use and included short presentations from speakers, followed by an open forum to allow questions, identify areas of concerns and share information.

Eudrac attended this Brexit stakeholder’s meeting and a short summary of the key points can be found here